Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valproic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.94 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.94 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.94 |
| ▸ | HTR2A | P28223 | 1/20 | 0.94 |
| ▸ | HTR2C | P28335 | 1/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.94 |
| ▸ | HRH1 | P35367 | 1/20 | 0.94 |
| ▸ | DRD3 | P35462 | 1/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.94 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.94 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.94 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.60 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.60 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.60 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valproic Acid SCHEMBL244738 | 1.00 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL6910916 | 1.00 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL1685069 | 1.00 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL7579608 | 1.00 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL27925984 | 0.97 | CHRM1 (0.89) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL28857465 | 0.97 | CHRM1 (0.89) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL2275 | 0.97 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL1330837 | 0.97 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL140241 | 0.97 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL28895465 | 0.95 | CHRM1 (0.84) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115025227-A | Methods and pharmaceutical compositions for the treatment of depression with combinations of drugs | 浙江大学 | 2022-09-09 | — | — | CN | claimed |
| CN-115025224-A | Method and medicament for treating depression by using T-type calcium ion channel inhibitor | 浙江大学 | 2022-09-09 | — | — | CN | claimed |
| CN-115025227-A | Methods and pharmaceutical compositions for the treatment of depression with combinations of drugs | 浙江大学 | 2022-09-09 | — | — | CN | disclosed |
| CN-115025224-A | Method and medicament for treating depression by using T-type calcium ion channel inhibitor | 浙江大学 | 2022-09-09 | — | — | CN | disclosed |
| CN-108853504-B | Modulation and use of T-type calcium channel inhibitors for depression | 浙江大学 | 2022-05-20 | — | — | CN | disclosed |
| CN-108853510-B | Treatment and medicaments for depression with a combination of an NMDAR inhibitor and a T-type calcium channel inhibitor | 浙江大学 | 2022-05-20 | — | — | CN | disclosed |
| US-20180250344-A1 | LITHIUM STIMULATION OF CORD BLOOD STEM CELL PROLIFERATION AND GROWTH FACTOR PRODUCTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3137086-A1 | METHOD OF TREATING RESISTANT NON-HODGKIN LYMPHOMA, MEDULLOBLASTOMA, AND/OR ALK+NON-SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix GmbH (CH) | 2017-03-08 | — | — | EP | disclosed |
| WO-2015168555-A1 | METHOD OF TREATING RESISTANT NON-HODGKIN LYMPHOMA, MEDULLOBLASTOMA, AND/OR ALK+NON-SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2015-11-05 | — | — | WO | disclosed |
| US-20150231184-A1 | LITHIUM STIMULATION OF CORD BLOOD STEM CELL PROLIFERATION AND GROWTH FACTOR PRODUCTION | UNIV RUTGERS (US) | 2015-08-20 | — | — | US | disclosed |
| CN-102911989-B | Lithium stimulation of cord blood stem cell proliferation and growth factor production | UNIV RUTGERS | 2015-07-22 | — | — | CN | disclosed |
| WO-2011143721-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2011-11-24 | — | — | WO | disclosed |
| EP-2331088-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2011-06-15 | — | — | EP | disclosed |
| US-20100189696-A1 | LITHIUM STIMULATION OF CORD BLOOD STEM CELL PROLIFERATION AND GROWTH FACTOR PRODUCTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2010-07-29 | — | — | US | disclosed |
| CN-101003476-B | Technique for preparing disodium valproate | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2010-05-12 | — | — | CN | disclosed |
| CN-101627114-A | Lithium stimulation of cord blood stem cell proliferation and growth factor production | UNIV RUTGERS | 2010-01-13 | — | — | CN | disclosed |
| EP-2089512-A2 | LITHIUM STIMULATION OF CORD BLOOD STEM CELL PROLIFERATION AND GROWTH FACTOR PRODUCTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008055224-A2 | LITHIUM STIMULATION OF CORD BLOOD STEM CELL PROLIFERATION AND GROWTH FACTOR PRODUCTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-05-08 | — | — | WO | disclosed |
| CN-101003476-A | Technique for preparing disodium valproate | UNIV QINGDAO TECHNOLOGICAL (CN) | 2007-07-25 | — | — | CN | disclosed |
| WO-2004054957-A2 | VALPROIC ACID ANALOGUES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2004-07-01 | — | — | WO | disclosed |